Rolland 1990.

Study characteristics
Methods	Trial design: parallel, randomised, double‐blind, double‐placebo study
Participants	Participants: 194 women were randomised; 170 were analysed. Mean age: between 18 and 45 years Inclusion criteria: Laparoscopically confirmed endometriosis 18‐45 years old Body weight of 45‐110kg Menstrual cycle of 24‐36 days Symptomatic Not pregnant Negative pap smear test Exclusion criteria: Prescence of amenorrhoea Interfering concurrent disease Surgical treatment at baseline laparoscopy or within 6 months prior to study Gonadal hormone or danazol use within 3 months prior to study Simultaneous participation in other studies Setting: 13 medical centres in seven European countries Timing: not stated
Interventions	Nafarelin 200 μg twice daily IN + placebo PO twice daily for 6 months (n = 127) versus Danazol 200 mg twice daily PO + placebo IN twice daily for 6 months (n = 67)
Outcomes	Pain defined by symptoms severity score Adverse effects  AFS score
Notes	Intention‐to‐treat analysis: not stated Sample size calculation: not stated Funding: not stated Authors contacted regarding methods and data. Letter returned with author unknown at Department
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomised 2:1 nafarelin: danazol. No further details of method used to generate the randomisation sequence were provided.
Allocation concealment (selection bias)	Unclear risk	No details of method used to conceal allocation were provided.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double‐placebo, double‐blind study
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Double‐placebo, double‐blind study
Incomplete outcome data (attrition bias) All outcomes	Low risk	Details for attrition: 20 in nafarelin and 4 in danazol group withdrew due to: adverse effects 7 (Naf) vs 2 (Dan) intercurrent illness 1 (Naf) vs 2 (Dan) personal reasons 3 (Naf) lost to follow‐up 3 (Naf) lack of drug efficacy 1 (Naf) other 5 (Naf) Nafarelin: 20/127 discontinued treatment. Danazol: 4/67 discontinued treatment.
Selective reporting (reporting bias)	Low risk	The study protocol was not available but it was clear that the published reports included all expected outcomes, including those that were prespecified.
Other bias	Low risk	No other risk of bias detected